Screening patient-derived tumor cell cultures against a drug library is a promising adjunct to clinical decision-making.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
O'Brien, S.G. et al. N. Engl. J. Med. 348, 994–1004 (2003).
Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).
Soria, J.C. et al. N. Engl. J. Med. 378, 113–125 (2018).
Tsimberidou, A.M. et al. JCO Precis. Oncol. 2017, https://doi.org/10.1200/PO.17.00002 (2017).
Wheler, J.J. et al. Cancer Res. 76, 3690–3701 (2016).
Lee, J.-K. et al. Nat. Genet. 50, 1399–1411 (2018).
Vlachogiannis, G. et al. Science 359, 920–926 (2018).
Gao, H. et al. Nat. Med. 21, 1318–1325 (2015).
Kodack, D.P. et al. Cell Rep. 21, 3298–3309 (2017).
Jacobsen, E., Shanmugam, V. & Jagannathan, J. N. Engl. J. Med. 377, 2398–2399 (2017).
Janku, F. et al. Cell Rep. 6, 377–387 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.K. receives research funding from Genentech, Incyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols and Guardant, as well as receiving consultant fees from Loxo, X Biotech, NeoMed and Actuate Therapeutics, receiving speaker fees from Roche, and holding an ownership interest in IDbyDNA and Curematch Inc.
Rights and permissions
About this article
Cite this article
Kato, S., Kurzrock, R. An avatar for precision cancer therapy. Nat Biotechnol 36, 1053–1055 (2018). https://doi.org/10.1038/nbt.4293
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4293